Nuclea Biotechnologies NanoMolecular DX Purchases Nuclea's Assets for $330K Premium Headed by Nuclea's former Founder and CEO Patrick Muraca, NanoMolecular aims to commercialize cancer diagnostics including Nuclea's Her2/neu assay. Nuclea's Former CEO Attempting to Buy Company's Assets in Bankruptcy Nuclea's trustee has requested the court approve sale of its assets, which failed to sell at auction, to a firm run by Nuclea's former CEO Patrick Muraca. Nuclea to Auction Assets as Part of Chapter 7 Bankruptcy Proceedings Premium Set for Jan. 18, 2017, the sale will feature assets including its HER-2/neu assay, a blood-based test for monitoring women with metastatic breast cancer. Nuclea, IRCM Partner to Validate Mass Spec Diabetes Assays Under the partnership the two companies will develop assays for insulin, proinsulin, and c-peptide on clinical sample cohorts at both Nuclea and IRCM's facilities. Nuclea Mass Spec Plans Take Shape with Upcoming Launches of RUO, Clinical Assays Premium The company will focus largely on applying mass spec to relatively established protein markers for which existing immunoassay-based tests have poor performance. Jun 30, 2015 Nuclea, Aelan Ink Biomarker Test, Companion Dx Deal Feb 27, 2015 Nuclea Bio Plans Entry into Clinical Proteomics with Launch of Mass Spec-based Assays in 2015 Premium Jun 6, 2014 Nuclea Inks Collaboration with Thermo Fisher to Develop Mass Spec Assays for Type 2 Diabetes Premium Jun 2, 2014 Nuclea, Thermo Fisher Collaborating on Mass Spec Assays for Type 2 Diabetes Apr 30, 2014 Clinical Reference Lab to Validate Nuclea's Assays Feb 21, 2014 IBL to Become Nuclea Bio's Primary US Distributor for Metastatic Breast Cancer Dx Feb 20, 2014 Foundation Medicine, Quanterix among Omics Firms Getting Massachusetts Tax Incentives Feb 18, 2014 Enzo to Market Nuclea's Metastatic Breast Cancer Dx Sep 9, 2013 Nuclea Biotech Buying Wilex's US Subsidiary Jun 20, 2013 Nuclea, SUNY College to Develop Nanochip for Cancer Diagnosis Jun 19, 2013 Nuclea Biotech, Berkshire Medical Center Collaborate on Prostate, Breast Cancer Biomarker Identification May 7, 2013 Nuclea Biotechnologies Attracts $4.2M in Series D Round Mar 20, 2013 Nuclea, Wilex Partner to Offer Breast Cancer Testing Service Feb 22, 2013 Nuclea Biotechnologies Raises $1.1M Toward $2.5M Financing Round Nov 9, 2012 Nuclea Biotechnologies Expands Office Space, Launches Research Partnership Premium Aug 3, 2012 In Brief This Week: Cepheid; Bruker; Illumina; PerkinElmer; Nuclea Biotechnologies Jul 19, 2012 Nuclea Acquires Tissue Microarray IP Apr 13, 2012 Nuclea Biotechnologies Initiates Series C Round Targeting $10M Mar 12, 2012 Nuclea Partners with Albany VA Institute in Prostate Cancer Marker Study Feb 2, 2012 Nuclea Announces $3.4M in Additional Financing Load More Breaking News Pediatric Medulloblastoma Subgroups May Benefit from Lower-Dose Radiation Therapy Space Radiation Shows Limited Effects on Mammalian Sperm DNA, Fertility Bluestar Genomics Sues Former Consultant, Ludwig Institute for Cancer Research Over IP Ownership New Products Posted to GenomeWeb: 10x Genomics, Swift Biosciences, Agilent Technologies, More In Brief This Week: Quantum-Si, TGen, Yale, and More People in the News: New Appointments at Invitae, PGDx, Oxford Nanopore, PacBio, More The Scan Fertility Fraud Found Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today. Ties Between Vigorous Exercise, ALS in Genetically At-Risk People Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports. Test Warning The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK. Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.